neurotrophic receptor tyrosine kinase 1
Last updated 18 Aug 2020
Meets Patient’s editorial guidelines
- DownloadDownload
- Share
- Language
- Discussion
- Ask Patient
- Audio Version
- Add to preferred sources on Google
The NTRK1 gene provides instructions for making a protein that is essential for the development and survival of nerve cells (neurons), especially those that transmit information about sensations such as pain, temperature, and touch (sensory neurons). The NTRK1 protein is found on the surface of cells, particularly sensory neurons. It acts as a kinase, which is an enzyme that changes the activity of other proteins by adding a cluster of oxygen and phosphorus atoms (a phosphate group) at specific positions. This process is called phosphorylation. The NTRK1 protein is turned on (activated) when another protein called nerve growth factor beta (NGFβ) attaches (binds) to it and signals the NTRK1 protein to phosphorylate itself (autophosphorylation). Then, the activated NTRK1 protein phosphorylates other proteins; this process is needed to transmit signals for cell growth and survival.
Video picks for GenesVideo library
Normal function
The NTRK1 gene provides instructions for making a protein that is essential for the development and survival of nerve cells (neurons), especially those that transmit information about sensations such as pain, temperature, and touch (sensory neurons). The NTRK1 protein is found on the surface of cells, particularly sensory neurons. It acts as a kinase, which is an enzyme that changes the activity of other proteins by adding a cluster of oxygen and phosphorus atoms (a phosphate group) at specific positions. This process is called phosphorylation. The NTRK1 protein is turned on (activated) when another protein called nerve growth factor beta (NGFβ) attaches (binds) to it and signals the NTRK1 protein to phosphorylate itself (autophosphorylation). Then, the activated NTRK1 protein phosphorylates other proteins; this process is needed to transmit signals for cell growth and survival.
Conditions referring to this gene or chromosome
Other names
high affinity nerve growth factor receptor
MTC
neurotrophic tyrosine kinase, receptor, type 1
NTRK1_HUMAN
p140-TrkA
TRK
Trk-A
TRK1
TRK1-transforming tyrosine kinase protein
TRKA
tyrosine kinase receptor A
Patient picks for Genes

PID Q&A
Does PID cause bleeding?
Dr Sarah Jarvis MBE Symptoms may develop quickly. You can become quite ill over a few days. Sometimes symptoms are mild and develop slowly. For example, you may just have a mild abdominal pain that may 'grumble on' for weeks. In some cases no symptoms develop and you do not know that you are infected. However, you are still at risk of complications even if you have no symptoms at first. [https://patient.info/health/pelvic-pain-in-women/pelvic-inflammatory-disease#nav-1](https://patient.info/health/pelvic-pain-in-women/pelvic-inflammatory-disease#nav-1)
by Dr Sarah Jarvis

PID Q&A
How do you diagnose PID?
Dr Sarah Jarvis MBE Symptoms may develop quickly. You can become quite ill over a few days. Sometimes symptoms are mild and develop slowly. For example, you may just have a mild abdominal pain that may 'grumble on' for weeks. In some cases no symptoms develop and you do not know that you are infected. However, you are still at risk of complications even if you have no symptoms at first. [https://patient.info/health/pelvic-pain-in-women/pelvic-inflammatory-disease#nav-1](https://patient.info/health/pelvic-pain-in-women/pelvic-inflammatory-disease#nav-1)
by Dr Sarah Jarvis

Breast cancer
How often is breast cancer misdiagnosed?
Dr Sarah Jarvis MBE Finding out the stage of the cancer, the grade of the cells and the receptor status of the cancer helps doctors to advise on the best treatment options. It also gives a reasonable indication of outlook. [https://patient.info/health/breast-cancer-leaflet#nav-5](https://patient.info/health/breast-cancer-leaflet#nav-5)
by Dr Sarah Jarvis

Risks of diabetes
What can someone with type 1 diabetes do to stop their glucose going too high?
Dr Sarah Jarvis MBE For more information on continuous glucose monitoring, go to [https://patient.info/health/type-1-diabetes/features/continuous-glucose-monitoring-in-type-1-diabetes](https://patient.info/health/type-1-diabetes/features/continuous-glucose-monitoring-in-type-1-diabetes)
by Dr Sarah Jarvis

IBS
What is an IBS attack?
Dr Sarah Jarvis MBE Irritable bowel syndrome (IBS) is a long-term (chronic) condition of the gut (bowel) that causes episodes of tummy (abdominal) cramps, bloating and either constipation or diarrhoea. IBS is a problem with how the bowel works. There is otherwise nothing wrong with the bowel. [https://patient.info/health/irritable-bowel-syndrome-leaflet#nav-1](https://patient.info/health/irritable-bowel-syndrome-leaflet#nav-1)
by Dr Sarah Jarvis

Medicine
Irbesartan - an angiotensin receptor blocker
Take irbesartan once each day. You can take the tablets before or after meals. Side-effects are usually mild. They include feeling dizzy and mild stomach upset. Keep your regular appointments with your doctor to have your blood pressure measured. Some painkillers interfere with irbesartan, so ask a pharmacist for advice before you buy any medicines.
by Michael Stewart, MRPharmS
Related patient information and medicines

Patient information leaflet
Mouth cancer
Epidermal growth factor receptor monoclonal antibody (EGFR mAb) is one form of targeted therapy. Cetuximab is an EGFR mAb. Tyrosine kinase inhibitors (TKIs) are another. Immunotherapy is treatment that aims to boost the body's own immune system to destroy the cancer cells. It is also sometimes called biological therapy: Recombinant interleukin.

Patient information leaflet
Chronic myeloid leukaemia
Treatment for the initial chronic phase The aim of treatment is to control the disease process, to ease any symptoms and to prevent (or delay) the progress... You may be advised to have one or more of the following treatments: Imatinib tablets. This medicine is known as a tyrosine kinase inhibitor. The chemical tyrosine kinase is made by the.

Patient information leaflet
Mastocytosis and mast cell disorders
If the condition is severe, surgery to remove the spleen (splenectomy), medicines that have an effect on ... Dr Sarah Jarvis , 28th September 2021 Midostaurin for treating advanced systemic mastocytosis The National Institute for Health and Care Excellence (NICE) has brought out new guidance on the use of midostaurin for people with mastocytosis..

Patient information leaflet
Nausea medicine
Ondansetron is also sometimes used to treat nausea and vomiting from gastroenteritis Gastroenteritis. Aprepitant Aprepitant to prevent sickness and fosaprepitant - these are newer medicines and work by blocking a chemical that acts on neurokinin receptors in the body to cause nausea. They are sometimes called neurokinin-1 receptor antagonists..

Patient information leaflet
Can I take Alogliptin and Rybelsus together?
Taking alogliptin and Rybelsus (semaglutide) together can significantly increase the risk of your blood sugar dropping too low (hypoglycaemia). Additionally, both medicines work in a similar way on the same hormonal pathway, and using them together is generally not recommended because it does not provide extra benefit but increases the....

Patient information leaflet
Myasthenia gravis
Myasthenia gravis (MG) is a condition where muscles become easily tired and weak. It is due to a problem with how the nerves stimulate the muscles to tighten (contract). The muscles become easily tired and weak. What causes myasthenia gravis. Myasthenia gravis is an autoimmune disease. This means that the immune system The immune system (which.
Further reading and references
- neurotrophic receptor tyrosine kinase 1; MedlinePlus, National Library of Medicine.
- Greco A, Miranda C, Pierotti MA. Rearrangements of NTRK1 gene in papillary thyroid carcinoma. Mol Cell Endocrinol. 2010 May 28;321(1):44-9. doi: 10.1016/j.mce.2009.10.009. Epub 2009 Oct 31.
- Indo Y, Tsuruta M, Hayashida Y, Karim MA, Ohta K, Kawano T, Mitsubuchi H, Tonoki H, Awaya Y, Matsuda I. Mutations in the TRKA/NGF receptor gene in patients with congenital insensitivity to pain with anhidrosis. Nat Genet. 1996 Aug;13(4):485-8. doi: 10.1038/ng0896-485.
- Indo Y. Molecular basis of congenital insensitivity to pain with anhidrosis (CIPA): mutations and polymorphisms in TRKA (NTRK1) gene encoding the receptor tyrosine kinase for nerve growth factor. Hum Mutat. 2001 Dec;18(6):462-71. doi: 10.1002/humu.1224.
- Kaplan DR, Miller FD. Neurotrophin signal transduction in the nervous system. Curr Opin Neurobiol. 2000 Jun;10(3):381-91. doi: 10.1016/s0959-4388(00)00092-1.
- Miranda C, Di Virgilio M, Selleri S, Zanotti G, Pagliardini S, Pierotti MA, Greco A. Novel pathogenic mechanisms of congenital insensitivity to pain with anhidrosis genetic disorder unveiled by functional analysis of neurotrophic tyrosine receptor kinase type 1/nerve growth factor receptor mutations. J Biol Chem. 2002 Feb 22;277(8):6455-62. doi: 10.1074/jbc.M110016200. Epub 2001 Nov 21.
- Pierotti MA, Greco A. Oncogenic rearrangements of the NTRK1/NGF receptor. Cancer Lett. 2006 Jan 28;232(1):90-8. doi: 10.1016/j.canlet.2005.07.043. Epub 2005 Oct 20.
- Verpoorten N, De Jonghe P, Timmerman V. Disease mechanisms in hereditary sensory and autonomic neuropathies. Neurobiol Dis. 2006 Feb;21(2):247-55. doi: 10.1016/j.nbd.2005.08.004. Epub 2005 Sep 23.
Share your thoughts or experiences with others in our patient communities.
Sign up to the Patient newsletter
Your weekly dose of clear, trustworthy health advice - written to help you feel informed, confident and in control.
By subscribing you accept our Privacy Policy. You can unsubscribe at any time. We never sell your data.

